Biogen is deeply committed to helping improve the lives of people with SMA, working closely with the SMA patient community with the goal of understanding and incorporating the perspectives of patients and families into the decisions we make. Following the approval of our treatment by the United States’ Food and Drug Administration (FDA) and the European Commission (EC), we are now working closely with national regulatory agencies to bring this therapy to patients in Europe as quickly as possible.